Spero Therapeutics, Inc.
SPRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001701108
No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Spero Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 60 | 2 | 48 | −10 |
| Shares | 14.2M | 17.6K | 14.3M | +44.6K (+0.3%) |
| Value | $24.6M | $30.2K | $20.6M | −$3.97M (−16.2%) |
2 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held Spero Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bridgeway Capital Management, LLC | 109,800 | $159.2K | 0.00% |
| WR Wealth Planners, LLC | 2,600 | $3.77K | 0.00% |
| Federation des caisses Desjardins du Quebec | 700 | $1.01K | 0.00% |
Sold out (13)
Institutions that held Spero Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Oasis Management Co Ltd. | 288,000 | $498.2K |
| Virtu Financial LLC | 34,369 | $59.0K |
| Two Sigma Securities, LLC | 23,523 | $40.7K |
| CI Private Wealth, LLC | 17,500 | $30.3K |
| Prudential Financial Inc | 14,600 | $25.3K |
| Sentinel Pension Advisors Inc | 12,000 | $20.8K |
| Stifel Financial Corp | 10,766 | $18.6K |
| Colony Group LLC | 10,000 | $17.0K |
| Simplex Trading, LLC | 9,206 | $15.0K |
| Belpointe Asset Management LLC | 4,560 | $7.89K |
| BNP Paribas Arbitrage, SA | 668 | $1.16K |
| Aspire Private Capital, LLC | 100 | $173 |
| Steward Financial Group LLC | 354 | $0 |
Not filed for Q1 2023 yet (2)
Institutions that held Spero Therapeutics, Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Gofen & Glossberg LLC | 17,500 | $30.0K |
| CoreCap Advisors, LLC | 142 | $246 |